Accel Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Accel Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133K	Sell	36,200 -3,000	-8%	-$9.99K	0.03%	300
2026 Q1	$120K	Sell	39,200 -1,000	-2%	-$3.86K	0.03%	284
2025 Q4	$164K	Sell	40,200 -4,000	-9%	-$19.8K	0.05%	271
2025 Q3	$216K	Hold	44,200	–	–	0.06%	253
2025 Q2	$224K	Buy	44,200 +150	+0.3%	+$737	0.07%	232
2025 Q1	$233K	Sell	44,050 -1,750	-4%	-$12.8K	0.08%	216
2024 Q4	$310K	Buy	+45,800	New	+$308K	0.12%	183
2023 Q3	–	Sell	-10,330	Closed	-$77.2K	–	179
2023 Q2	$77.2K	Buy	10,330 +4,230	+69%	+$29.6K	0.04%	167
2023 Q1	$40.7K	Buy	+6,100	New	+$48.4K	0.02%	522

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

NWMG

National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

IIA

Integral Investment Advisors Turlock, California $454M AUM 21.42% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Accel Wealth Management's RXRX Position: Q2 2026 in Review

Accel Wealth Management reduced its Recursion Pharmaceuticals (RXRX) stake by 7.7% in Q2 2026, selling an estimated $9.99K and leaving 36,200 shares worth $133K. The position accounts for 0.03% of the portfolio, ranked #300.

Accel Wealth Management first reported a position in RXRX in Q1 2023 and has held it in 9 quarters since. The position peaked at $310K in Q4 2024. 24 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Accel Wealth Management held 36,200 shares of Recursion Pharmaceuticals worth $133K as of Q2 2026.
Accel Wealth Management sold 3,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $9.99K.
Recursion Pharmaceuticals made up 0.03% of Accel Wealth Management's portfolio in Q2 2026, its #300 holding.
Accel Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 9 quarters since.
Accel Wealth Management's Recursion Pharmaceuticals position peaked at $310K in Q4 2024.
24 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Accel Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.